The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Conditions
Metastatic Castration-resistant Prostate Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Chao Family Comprehensive Cancer Centre, Orange, California, United States
Biogenix Molecular LLC, Miami, Florida, United States
United Theranostics, Glen Burnie, Maryland, United States
XCancer Omaha, Omaha, Nebraska, United States
Columbia University Herbert Irving Comphrensive Cancer Center, New York, New York, United States
Contact: Principal Investigator (Mark Stein)University Hospital, Cleveland, Ohio, United States
OHSU Knight Cancer Center, Portland, Oregon, United States
Intermountain Health, Murray, Utah, United States
Intermountain Health, Salt Lake City, Utah, United States
Westmead Hospital, Sydney, New South Wales, Australia
Contact: Study coordinator (Westmead Hospital) · wslhd-cpmcc-enquiries@health.nsw.gov.au · +61 2 8890 5200Contact: Principal Investigator (Dr. Tania Moujaber)Nepean Hospital, Sydney, New South Wales, Australia
Contact: Principal Investigator (Dr. Veronica Wong)Wollongong Hospital, Wollongong, New South Wales, Australia
Contact: Study coordinator (Carly Leighton) · ISLHD-CancerClinicalTrials@health.nsw.gov.au · +61 2 4222 5200Contact: Principal Investigator (Dr. Gary Tincknell)Australian Prostate Centre, Melbourne, Victoria, Australia
Contact: Principal Investigator (Prof. Tony Costello)GenesisCare Murdoch, Perth, Western Australia, Australia
Contact: Principal Investigator (Dr. Aviral Singh)Mater Health Services Pty Ltd, Brisbane, Australia
Contact: Principal Investigator (Niara Oliveira)GenesisCare Maitland, East Maitland, Australia
Contact: Principal Investigator (Sangeetha Ramanujan)Austin Health, Heidelberg, Australia
GensisCare Cabrini, Malvern, Australia
Contact: Principal Investigator (Mario Guerrieri)GenesisCare North Adelaide, North Adelaide, Australia
Contact: Study coordinator (Geetanjali Rangnekar) · geetanjali.rangnekar@genesiscare.com · +61 882158010Contact: Principal Investigator (Tony Michele)Royal North Shore Hospital, Saint Leonards, Australia
Contact: Principal Investigator (Alexander Guminski)GenesisCare Tugun, Tugun, Australia
Contact: Principal Investigator (Sagar Ramani)INITIO Medical Group, Burnaby, Canada
Sunnybrook Research Institute, Toronto, Canada
Contact: Principal Investigator (Urban Emmenegger)Auckland City Hospital, Grafton, Auckland, New Zealand
Contact: Study coordinator (Sergei Bendrikovskii) · Ak-Researchassistant@TeWhatuOra.govt.nz · +64 93074949Contact: Principal Investigator (Simon Fu)New Zealand Clinical Research - Christchurch, Christchurch, New Zealand
Contact: Principal Investigator (Anthony Rahman)Ankara Bilkent City Hospital, Ankara, Turkey (Türkiye)
Contact: Principal Investigator (Elif Özdemir)Ankara University Cebeci Hospital, Ankara, Turkey (Türkiye)
Contact: Principal Investigator (Yuksel Urun)Hacettepe University Medical Faculty, Ankara, Turkey (Türkiye)
Contact: Principal Investigator (Murat Bozkurt)Maslak Acibadem Hospital, Istanbul, Turkey (Türkiye)
Contact: Study coordinator (Doğukan Danışmant) · dogukan.danismant@medismart.com.tr · +90 545 862 87 19Contact: Principal Investigator (Tevfik F Cermik)University College London Hospitals, London, United Kingdom
Contact: Principal Investigator (Ursula McGovern)Genesis Care Windsor, Windsor, United Kingdom
Contact: Principal Investigator (Nicola Dallas)